Japanese Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Medicago, a biopharma company that develops vaccines, in a deal valued at nearly $357m. Based on the terms of the definitive agreement, the acquirer will purchase all of the ...
Tags: Mitsubishi, Pharma, Medicago
UK-based NextPharma Technologies has been selected by Mitsubishi Pharma Europe (MPE) to provide tailored, primary and secondary packaging solutions for its BindRen, within the European territory. MPE, the European subsidiary of Mitsubishi ...
Tags: NextPharma, Packaging
Mitsubishi Tanabe Pharma is seeking manufacturing and marketing approval of TA-7284 (generic name: canagliflozin) in Japan. The company filed a new drug application to the Ministry of Health, Labor and Welfare in Japan for TA-7284 to ...
Tags: Mitsubishi, canagliflozin
The US food and drug administration (FDA) has approved Janssen's Invokana (canagliflozin) for the treatment of adults with type 2 diabetes. Invokana is the oral, once-daily medication available in the US demonstrating improved glycemic ...
Janssen Research & Development has submitted a new drug application (NDA) to the FDA for canagliflozin to treat adult patients with type 2 diabetes. The filing is based on a global Phase III clinical development program, including nine ...
Tags: Janssen Research&Development, SGLT2, cardiovascular study
Mitsubishi Tanabe Pharma has deployed ArisGlobal's new pharmacovigilance and clinical safety solutions including ARISg and ARISj. ARISg and ARISj solutions are designed for collecting, assessing, distributing and managing adverse ...
Cytochroma has announced termination of a license agreement with Mitsubishi Tanabe Pharma (MTPC) thereby regaining rights to all indications of lunacalcipol indications in the US and in Asian territories. The companies mutually decided to ...
Tags: Cytochroma, Mitsubishi Tanabe Pharma, lunacalcipol indications
Mitsubishi Tanabe Pharma is introducing Depas tablets 0.25mg, a new dosage to be added to the series of tranquilizer being currently available under the brand names Depas tablets 0.5mg, Depas tablets 1gm and Depas fine granules 1%, in ...
Tags: Mitsubishi, Depas tablets, Antipsychotic
Mitsubishi Tanabe Pharma has announced the transfer of its fine chemical operations to two different companies and withdrawal from the fine chemical business. The Pharmaceutical ingredient manufacturing and sales operations will be ...
Tags: fine chemical operations, API, Mitsubishi Tanabe Pharma
Vivus has received NDA approval for TA-1790 (avanafil), indicated for the treatment of erectile dysfunction (ED), in the US. VIvus will market the product under the brand name Stendra in the US. Mitsubishi Tanabe Pharma has ...
Tags: avanafil, erectile dysfunction, pharmaceutical product